摘要
目的:比较沙库巴曲缬沙坦和缬沙坦对心力衰竭(简称心衰)患者的治疗效果。方法:选取2018年10月至2019年6月安徽省阜阳市太和县人民医院心血管内科收治的心衰患者120例作为研究对象,通过SPSS软件随机分为缬沙坦组和沙库巴曲缬沙坦组,每组60例。缬沙坦组在常规治疗的基础上服用缬沙坦,沙库巴曲缬沙坦组在常规治疗的基础上服用沙库巴曲缬沙坦,比较两组患者一般资料及用药期间药品不良反应(ADRs)发生情况,分别检测并比较两组治疗前及治疗12周后每搏输出量(stroke volume,SV)、左室舒张末径(left ventricular end-diastolic diameter,LVEDD)、左室射血分数(left ventricular ejection fraction,LVEF)、6分钟步行试验(6-minute walk test,6MWT)、氨基末端脑钠肽(N-terminal brain natriuretic peptide,NT-BNP)、心肌肌钙蛋白I(cardiac troponin I,cTnI)水平。结果:两组患者的性别、年龄、纽约心脏病协会心功能分级及原发疾病等一般资料差异无统计学意义(P>0.05)。沙库巴曲缬沙坦组治疗后的LVEF、SV、6MWT均明显高于治疗前及缬沙坦组治疗后,LVEDD、NT-BNP、cTnI明显低于治疗前及缬沙坦组治疗后,差异有统计学意义(P<0.05)。沙库巴曲缬沙坦组ADRs发生率为13.33%,与缬沙坦组的15.00%比较,差异无统计学意义(P>0.05)。结论:与缬沙坦相比,沙库巴曲缬沙坦对心衰患者心功能改善及缓解心肌损伤的效果更好,且不会增加ADRs发生率,值得临床推广。
Objective:To compare the therapeutic efficacy of sacubitril/valsartan and valsartan in the treatment of patients with heart failure(HF).Methods:120 HF patients admitted into the Department of Cardiovasology,People’s Hospital of Taihe County,Fuyang City of Anhui Province from October 2018 to June 2019 were enrolled as research subjects.The patients were randomly divided into the sacubitril/valsartan group and the valsartan group using SPSS software,each consisting of 60 patients.The patients in the valsartan group took valsartan on the basis of conventional treatment,while the patients in the sacubitril/valsartan group received sacubitril/valsartan on the basis of conventional treatment.The general data and adverse drug reactions(ADRs)were compared between the patients of the two groups.The levels of stroke volume(SV),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),6-minute walk test(6MWT),N-terminal brain natriuretic peptide(NT-BNP),and cardiac troponin I(cTnI)were measured and compared between the groups before and 12 weeks after treatment.Results:No statistical significance could be noted in gender,age,New York Heart Association cardiac function classification and primary diseases in the patients of the two groups(P>0.05).After treatment,LVEF,SV and 6MWT levels in the patients of the sacubitril/valsartan group were significantly higher than those before treatment and after treatment in the valsartan group,and the levels of LVEDD,NT-BNP and cTnI in the sacubitril/valsartan group were significantly lower than those before treatment and after treatment in the valsartan group,with statistical significance(P<0.05).The total rate of ADRs in the sacubitril/valsartan group was 13.33%,and statistical significance could neither be seen as compared with the rate of the valsartan group(15.00%)(P>0.05).Conclusion:As compared with valsartan,sacubitril/valsartan could achieve better effects on the improvement of cardiac function and alleviation of myocardial injury in the patients wit
作者
樊晖晖
张磊
李宇
王运红
FAN Huihui;ZHANG Lei;LI Yu;WANG Yunhong(Department of Pharmacy,People’s Hospital of Taihe County,Fuyang City of Anhui Province,Anhui Fuyang 236600,China;Department of Cardiovasology,People’s Hospital of Taihe County,Fuyang City of Anhui Province,Anhui Fuyang 236600,China)
出处
《药学服务与研究》
CAS
2020年第4期251-254,共4页
Pharmaceutical Care and Research
关键词
沙库巴曲缬沙坦
缬沙坦
心力衰竭
疗效评价
sacubitril/valsartan
valsartan
heart failure
efficacy evaluation
